文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

多西环素对小腹主动脉瘤生长的随机临床试验

Effect of Doxycycline on Aneurysm Growth Among Patients With Small Infrarenal Abdominal Aortic Aneurysms: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2020-01-01

该多中心随机临床试验纳入261例50岁以上小肾下腹主动脉瘤患者,比较口服多西环素100mg每日两次与安慰剂治疗2年的效果。主要终点为CT测量的瘤体最大横径变化,结果显示两组无显著差异,不支持使用多西环素减缓小腹主动脉瘤生长。

要点

  • 多西环素未显著减缓小肾下腹主动脉瘤2年内的最大横径增长。
  • 2年时多西环素组与安慰剂组的直径变化均为0.36 cm,差异无统计学意义。
  • 两组不良事件(如关节痛)发生率相似,无患者因不良反应退出。

核心结论

  • 在小肾下腹主动脉瘤患者中,与安慰剂相比,多西环素未显著减少2年内的动脉瘤生长。
  • 这些发现不支持使用多西环素来减缓小腹主动脉瘤的生长。

研究设计与样本

  • 平行两组随机临床试验,在美国22个临床中心开展,2013年5月至2017年1月入组。
  • 纳入50岁及以上、男性瘤径3.5-5.0 cm、女性3.5-4.5 cm的小肾下腹主动脉瘤患者。
  • 随机分为多西环素100 mg口服每日两次组(n=133)和安慰剂组(n=128),治疗2年。
  • 最终分析集为多西环素组129例和安慰剂组125例,平均年龄71.0岁(SD 7.4),女性35例(14%)。

主要发现

  • 2年随访时,多西环素组96例最大横径变化0.36 cm(95%CI 0.31-0.40),安慰剂组101例0.36 cm(95%CI 0.30-0.41)。
  • 无患者因不良反应退出研究;关节痛在多西环素组发生84/129例(65%),安慰剂组79/125例(63%)。

临床怎么用

  • 对于小肾下腹主动脉瘤患者,不应常规使用多西环素来延缓瘤体生长。
  • 多西环素在此人群中的关节痛等不良反应发生率与安慰剂相似。

局限性

  • 7例(3%)患者未获得随访CT扫描,最终分析集少于随机例数。
  • 主要分析中部分直径数据为插补值(多西环素组88%、安慰剂组90%基于测量或插补直径)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Abdominal aortic aneurysms affect more than 3% of US older adults. OBJECTIVE: To test whether doxycycline reduces the growth of abdominal aortic aneurysm over 2 years as measured by maximum transverse diameter. DESIGN, SETTING, AND PARTICIPANTS: Parallel, 2-group, randomized clinical trial that was conducted at 22 US clinical centers between May 2013 and January 2017, and enrolled patients 50 years or older with small (3.5-5.0 cm for men, 3.5-4.5 cm for women) infrarenal aneurysms. The final date of follow-up was July 31, 2018. INTERVENTIONS: Patients were randomized to receive twice daily for 2 years doxycycline 100 mg orally (as capsules) (n = 133) or placebo (n = 128). MAIN OUTCOMES AND MEASURES: The primary outcome was change in abdominal aortic aneurysm maximum transverse diameter measured from CT images at baseline and follow-up at 2 years. Patients were assigned ranks based on the maximum transverse diameter (measured or imputed) of the aorta and also if they underwent aneurysm repair or died. The ranks were converted to scores having a normal distribution to facilitate the primary analysis ("normal scores"). RESULTS: Of 261 patients randomized, no follow-up CT scans were obtained on 7 (3%), leaving a final analysis set of 129 patients assigned to doxycycline and 125 to placebo (mean [SD] age, 71.0 years [7.4 years], 35 women [14%]). The outcome normal scores used in the primary analysis were based on maximum transverse diameter (measured or imputed) in 113 patients (88%) in the doxycycline group and 112 patients (90%) in the placebo group; aneurysm repair in 13 (10%) and 9 (7%), and death in 3 (2%) and 4 (3%), respectively. The primary outcome, normal scores reflecting change in aortic diameter, did not differ significantly between the 2 groups, mean change in normal scores, 0.0262 vs -0.0258 (1-sided P = .71). Mean (SD) baseline maximum transverse diameter was 4.3 cm (0.4 cm) for doxycycline and 4.3 cm (0.4 cm) for placebo. At the 2-year follow-up, the change in measured maximum transverse diameter was 0.36 cm (95% CI, 0.31 to 0.40 cm) for 96 patients in the doxycycline group vs 0.36 cm (95% CI, 0.30 to 0.41 cm) for 101 patients in the placebo group (difference, 0.0; 95% CI, -0.07 to 0.07 cm; 2-sided P = .93). No patients were withdrawn from the study because of adverse effects. Joint pain occurred in 84 of 129 patients (65%) with doxycycline and 79 of 125 (63%) with placebo. CONCLUSIONS AND RELEVANCE: Among patients with small infrarenal abdominal aortic aneurysms, doxycycline compared with placebo did not significantly reduce aneurysm growth at 2 years. These findings do not support the use of doxycycline for reducing the growth of small abdominal aortic aneurysms. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01756833.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Baxter BT, Matsumura J, Curci JA, et al. Effect of Doxycycline on Aneurysm Growth Among Patients With Small Infrarenal Abdominal Aortic Aneurysms: A Randomized Clinical Trial. JAMA. 2020. PMID: 32453369. doi:10.1001/jama.2020.5230

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。